tirzepatide super obesity bmi 60 and health‐related quality of life in adults with or overweight: Results from the SURMOUNT‐3 phase 3 randomized trial - Gibble - 2025 - Diabetes, Obesity and Metabolism What to Do When Your

India's obesity drug market could grow to 80 billion rupees ($856.6 million) by 2030 from about 15 billion rupees today, according to Pharmarack estimates Also Read: Novo Nordisk to Invest USD 506 Million to Expand Oral GLP-1 Drug Manufacturing in Ireland .EYES ON THE PRICE Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%

Both are administered as once-weekly subcutaneous injections using prefilled pens in the same dose range

Gently swirl do not shake or vortex

Proton pump inhibitors, H2 receptor antagonists, and prokinetic agents may have altered effectiveness due to tirzepatides effects on gastric function

While the clinical data is extraordinarily promising, we never overpromise

We suggest it is reasonable for inpatients to restart GLP- 1 RAs when resuming their usual diet (Grade E)